Tyra Biosciences, INC Form 4 insider transactions

Todd Harris, President and CEO and a Director of Tyra Biosciences, Inc., received 864 shares of common stock on September 15, 2026.

Yuliya Rueb, Vice President, Finance (PAO) of Tyra Biosciences, Inc., received 2,925 shares of common stock on September 15, 2026.

Alan Fuhrman, Chief Financial Officer of Tyra Biosciences, Inc., received 951 shares of common stock on September 15, 2026.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Tyra Biosciences, Inc. common stock on September 15, 2026.

Rehan Verjee, a Director of Tyra Biosciences, Inc., purchased 972 shares of common stock on September 9, 2026 for $20.58 per share.

RA Capital Management reports a stock option grant for director Dr. Jake Simson under the Tyra Biosciences non-employee director compensation program.

Tyra Biosciences Director Rehan Verjee was granted stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Susan Moran acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Jake Simson acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Adele M. Gulfo acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Robert J. More acquired stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Stephen Rothenberg acquired stock options for 13,160 shares of common stock.

Bhavesh Ashar, Chief Operating Officer of Tyra Biosciences, Inc., reported a transaction involving the acquisition of restricted stock units and stock options.

Yuliya Rueb, Vice President of Finance at Tyra Biosciences, acquired stock options and restricted stock units.

Director Habib J. Dable was granted 44,400 stock options in Tyra Biosciences, Inc. as part of a standard equity incentive.

Tyra Biosciences Director Gilla Kaplan exercised stock options and subsequently sold over 67,000 shares of common stock for approximately $2.5 million.

Tyra Biosciences Chief Financial Officer Alan Fuhrman acquired 1,376 shares of common stock through an employee stock purchase plan.

Tyra Biosciences President and CEO, Todd Harris, acquired 1,463 shares of common stock through the company's Employee Stock Purchase Plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on February 12, 2026, under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on January 12, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Tyra Biosciences Director Robert J. More sold 10,000 shares of common stock at $25 per share on December 19, 2025, under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, reported the sale of 8,000 common shares on December 12, 2025, executed under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Bhavesh Ashar, was granted 300,000 stock options with an exercise price of $20.81, vesting over four years.

Tyra Biosciences Director Robert J. More sold 246,871 shares of common stock for approximately $20.25 per share through a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold a total of 125,589 shares of common stock in two transactions in November 2025 under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold 131,411 shares of common stock in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Financial Officer, Alan Fuhrman, acquired 701 shares of common stock at $9.129 per share through the company's Employee Stock Purchase Plan.

Tyra Biosciences' Chief Financial Officer, Alan Fuhrman, was granted 170,000 stock options with a $10.75 exercise price, vesting monthly over four years.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, was granted 170,000 stock options with a $10.75 exercise price, vesting over four years.

Tyra Biosciences' Chief Medical Officer, Douglas J. Warner, was granted 200,000 stock options with a $10.75 exercise price and a 10-year expiration.